环磷腺苷葡胺治疗慢性心力衰竭临床疗效观察(1)
摘 要：目的 观察分析环磷腺苷葡胺治疗慢性心力衰竭的临床效果。方法 选取2016年1月～2017年2月我院收治的86例慢性心力衰竭患者为研究对象，将其随机分为观察组与对照组，每组43例。对照组给予常规抗心衰治疗，观察组在对照组的基础上给予环磷腺苷葡胺治疗，观察并对比两组患者治疗前后的心功能改善情况及LVEDD、LVESD、LVEF、BNP(脑钠肽)临床指标及不良反应发生情况。结果 观察组的治疗总有效率为93.02%，高于对照组的79.06%，差异有统计学意义(P<0.05)；观察组接受治疗后的各项心功能指优于对照组，差异有统计学意义(P<0.05)；两组的不良反应发生率均低，差异无统计学意义。结论 腺苷葡胺治疗慢性心力衰竭能有效改善患者的症状，各项心功能指标改善显著，临床效果显著，且具有一定的安全性，值得临床推广使用。
关键词：环磷腺苷葡胺；慢性心力衰竭；心功能
中图分类号：R541.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.10.045
, 百拇医药
文章编号：1006-1959(2018)10-0135-03
Clinical Efficacy of Cyclic Adenosine Glucosamine in the Treatment of Chronic Heart Failure
HE Ming-qing，LIU Xiao-ya
(Department of Internal Medicine，Jintang Traditional Chinese Medicine Hospital，Jintang 610400，Sichuan，China)
Abstract：Objective To observe and analyze the clinical effect of cyclic adenosine glucosamine in the treatment of chronic heart failure.Methods 86 patients with chronic heart failure treated in our hospital from January 2016 to February 2017 were selected and divided into the observation group and the control group，43 cases in each group.The control group was treated with normal anti heart failure，and the patients in the observation group were treated with cyclic adenosine glucosamine on the basis of the control group.Observe and compare the two groups of patients before and after treatment of cardiac function improvement and LVEDD，LVESD， LVEF，BNP(brain natriuretic peptide)clinical indicators and adverse reactions.Results The total effective rate of treatment in the observation group was 93.02% which was higher than that in the control group 79.06%，the difference was statistically significant(P< 0.05)，the cardiac function index after treatment in the observation group was better than that in the control group，the difference was statistically significant(P<0.05)；the incidence of adverse reactions in both groups was low and the difference was not statistically significant.Conclusion The treatment of chronic heart failure with adenosine glucosamine can effectively improve the symptoms of the patients.The indexes of heart function are improved significantly， the clinical effect is remarkable， and it has certain safety.It is worthy of clinical application.
, 百拇医药
Key words：Cyclic adenosine glucosamine；Chronic heart failure；Cardiac function
心力衰竭(heart failure)的基本病因主要由原發心肌损害和心脏长期容量和或压力负荷过重导致心肌功能由代偿最终发展为失代偿，慢性心力衰竭是心血管疾病最主要死因之一，是21世纪心血管领域的两大挑战之一。据统计，70岁以上人群患病率达10%以上，心力衰竭患者4年死亡率达50%，严重心衰患者1年死亡率高达50%[1]，对患者的生命造成严重的威胁，所以临床积极有效安全的治疗尤为重要。按照心衰治疗指南，增加心肌收缩力和心输出量，是慢性心力衰竭治疗的要点。环磷腺苷葡胺是近年来合成的一种非洋地黄、非儿茶酚胺正性肌力药物[2]，能够扩张冠状动脉血管，降低心肌耗氧量，从而保护缺血、缺氧的心肌细胞，从而达到治疗心衰的作用。本文旨在研究在常规治疗心力衰竭药物的基础上加用环磷腺苷葡胺的疗效和安全性，现报告如下。, http://www.100md.com(贺明清 刘孝娅)
关键词：环磷腺苷葡胺；慢性心力衰竭；心功能
中图分类号：R541.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.10.045
, 百拇医药
文章编号：1006-1959(2018)10-0135-03
Clinical Efficacy of Cyclic Adenosine Glucosamine in the Treatment of Chronic Heart Failure
HE Ming-qing，LIU Xiao-ya
(Department of Internal Medicine，Jintang Traditional Chinese Medicine Hospital，Jintang 610400，Sichuan，China)
Abstract：Objective To observe and analyze the clinical effect of cyclic adenosine glucosamine in the treatment of chronic heart failure.Methods 86 patients with chronic heart failure treated in our hospital from January 2016 to February 2017 were selected and divided into the observation group and the control group，43 cases in each group.The control group was treated with normal anti heart failure，and the patients in the observation group were treated with cyclic adenosine glucosamine on the basis of the control group.Observe and compare the two groups of patients before and after treatment of cardiac function improvement and LVEDD，LVESD， LVEF，BNP(brain natriuretic peptide)clinical indicators and adverse reactions.Results The total effective rate of treatment in the observation group was 93.02% which was higher than that in the control group 79.06%，the difference was statistically significant(P< 0.05)，the cardiac function index after treatment in the observation group was better than that in the control group，the difference was statistically significant(P<0.05)；the incidence of adverse reactions in both groups was low and the difference was not statistically significant.Conclusion The treatment of chronic heart failure with adenosine glucosamine can effectively improve the symptoms of the patients.The indexes of heart function are improved significantly， the clinical effect is remarkable， and it has certain safety.It is worthy of clinical application.
, 百拇医药
Key words：Cyclic adenosine glucosamine；Chronic heart failure；Cardiac function
心力衰竭(heart failure)的基本病因主要由原發心肌损害和心脏长期容量和或压力负荷过重导致心肌功能由代偿最终发展为失代偿，慢性心力衰竭是心血管疾病最主要死因之一，是21世纪心血管领域的两大挑战之一。据统计，70岁以上人群患病率达10%以上，心力衰竭患者4年死亡率达50%，严重心衰患者1年死亡率高达50%[1]，对患者的生命造成严重的威胁，所以临床积极有效安全的治疗尤为重要。按照心衰治疗指南，增加心肌收缩力和心输出量，是慢性心力衰竭治疗的要点。环磷腺苷葡胺是近年来合成的一种非洋地黄、非儿茶酚胺正性肌力药物[2]，能够扩张冠状动脉血管，降低心肌耗氧量，从而保护缺血、缺氧的心肌细胞，从而达到治疗心衰的作用。本文旨在研究在常规治疗心力衰竭药物的基础上加用环磷腺苷葡胺的疗效和安全性，现报告如下。, http://www.100md.com(贺明清 刘孝娅)